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A new series of eighteen imidazo [2,1-b] [1,3,4]thiadiazole derivatives was efficiently synthesized and
screened for antiproliferative activity against the National Cancer Institute (NCI-60) cell lines panel. Two
out of eighteen derivatives, compounds 12a and 12h, showed remarkably cytotoxic activity with the half
maximal inhibitory concentration values (IC50) ranging from 0.23 to 11.4 mM, and 0.29e12.2 mM,
respectively. However, two additional compounds, 12b and 13g, displayed remarkable in vitro anti-
proliferative activity against pancreatic ductal adenocarcinoma (PDAC) cell lines, including immortalized
(SUIT-2, Capan-1, Panc-1), primary (PDAC-3) and gemcitabine-resistant (Panc-1R), eliciting IC50 values
ranging frommicromolar to sub-micromolar level, associated with significant reduction of cell-migration
and spheroid shrinkage. These remarkable results might be explained by modulation of key regulators of
epithelial-to-mesenchymal transition (EMT), including E-cadherin and vimentin, and inhibition of
metalloproteinase-2/-9. High-throughput arrays revealed a significant inhibition of the phosphorylation
of 45 tyrosine kinases substrates, whose visualization on Cytoscape highlighted PTK2/FAK as an
important hub. Inhibition of phosphorylation of PTK2/FAK was validated as one of the possible mech-
anisms of action, using a specific ELISA. In conclusion, novel imidazothiadiazoles show potent anti-
proliferative activity, mediated by modulation of EMT and PTK2/FAK.
© 2020 Elsevier Masson SAS. All rights reserved.1. Introduction
The synthesis of hybrid molecules, bearing two or more
different biologically active scaffolds in a single structure, ise Tecnologie Biologiche Chi-
tudi di Palermo, Via Archirafi
ology, Amsterdam University
terdam, De Boelelaan 1117,
nl (E. Giovannetti), patrizia.
served.regarded as one of the most valuable approaches in drug devel-
opment in order to obtain new therapeutic strategies to treat
oncological diseases [1e3].
The design of anticancer drugs characterized by two moieties
with antitumor activity led to the development of a number of
molecules with improved biological potential compared to the
parent compounds. In particular, hybrid anticancer drugs showed
improved specificity, a greater ability to overcome drug-resistance
mechanisms, better patient compliance and lower side effects [4,5].
The simultaneous presence of two pharmacophores often led to
a synergism of the biological activities and therefore to the capa-
bility to act towardsmore than one target. Many examples of hybrid
compounds with promising cytotoxic properties have been
S. Cascioferro et al. / European Journal of Medicinal Chemistry 189 (2020) 1120882reported in the latest years. Singla and collaborators described
remarkable antiproliferative activity against the NCI-60 cell lines
panel of benzimidazole-triazine hybrids 1 (Fig. 1) which showed
IC50 values from the low micromolar to the nanomolar range [6].
The pyrimidine-triazole hybrids 2 (Fig. 1) exhibited potent anti-
cancer activity against the B16eF10 murine melanoma cancer cell
line due to their ability in reducing the pro-caspase 3 level while
increasing the p53 and active-caspase 3 levels [7]. Pyrazole-
benzofuran hybrids 3 (Fig. 1) emerged as promising anticancer
compounds against human pancreatic (Panc-1 and PaCa-2 cells),
lung (A549 and H-460), breast (MCF-7), colon (HT-29) and prostate
(PC-3) cancer, with IC50 values in the range of 0.9e2.2 mM (Fig. 1)
[8].
The imidazo [2,1-b] [1,3,4]thiadiazole nucleus has been consid-
ered a privileged scaffold for the development of molecules with
various pharmacological activities, such as anticancer [9], analgesic
[10], anti-leishmanial [11], antioxidant [12], antitubercular [13],
anticonvulsant [14], and antibacterial [15,16].
Concerning the antitumor activity, many imidazo [2,1-b] [1,3,4]
thiadiazole derivatives have been described as potent anticancer
molecules acting on several targets against different tumor models.
Compound 4 (Fig. 2) showed potent inhibitory activity
(IC50 ¼ 1.2 nM) against the activin receptor-like kinase 5 (ALK5)
proving to be selective toward the P38a kinase [17]. The imidazo
[2,1-b] [1,3,4]thiadiazole-5-carbaldehyde 5 (Fig. 2) was three fold
more potent than melphalan, used as reference drug, against mu-
rine (L1210) and human (CEM) leukemia cells as well as against
immortalized cervical cancer (HeLa) cells, eliciting IC50 values of
0.89 mM, 0.75 mM and 0.90 mM, respectively [18].
In the last decade the indole ring has emerged among the
scaffolds recognized as privileged pharmacophores for the devel-
opment of new antitumor compounds [19e26].
The indole derivative 6 was described for its potent anti-
proliferative activity against diffuse malignant peritoneal meso-
thelioma (DMPM) cell. Nortopsentin analogue 6 potently inhibited
CDK1 activity eliciting an IC50 value of 0.86 mM and consequently
induced a marked cell cycle arrest at the G2/M phase, which wasFig. 1. Chemical structures of benzimidazole-triazine hybrids 1, pparalleled by an increase in the apoptotic rate [27].
Therefore, on the basis of the interesting anticancer properties
described for imidazo [2,1-b] [1,3,4]thiadiazole and indole scaffolds,
we decided to evaluate the cytotoxic activity of a library of thirty-
six 3-(6-phenylimidazo [2,1-b] [1,3,4]thiadiazol-2-yl)-1H-indole
derivatives. In particular derivative 7 (Fig. 3) was effective against
all the tested cancer cell lines showing GI50 values ranging from
1.02 to 9.21 mM [28].
These preliminary results prompted further studies on nitrogen
heterocyclic systems endowedwith antitumor activity [29e35] and
we synthesized eighteen new 3-(imidazo [2,1-b] [1,3,4]thiadiazol-
2-yl)-1H indole analogues in order to evaluate how structural
modifications on the indole nucleus, introduction of an aldehyde
group at the position 5 of the imidazothiadiazole scaffold or the
replacement of the phenyl ring at the position 6 with a thiophene
ring could influence the anticancer activity of this class of
compounds.
We decided to test our new compounds on clinically-relevant
models of pancreatic ductal adenocarcinoma (PDAC). This tumor
is an extremely aggressive neoplasm, predicted to become the
second leading cause of cancer-related deaths before 2030 [36].
Cytotoxic chemotherapy remains the mainstay of treatment for
most PDAC patients. Treatment with 5-fluorouracil, leucovorin,
irinotecan and oxaliplatin (FOLFIRINOX) or with a combination of
gemcitabine and nab-paclitaxel, represent the standard-of-care for
unresectable patients, and recent data support the use of FOLFIR-
INOX as adjuvant therapy after surgical resection [37]. However,
PDAC is broadly chemoresistant, with a 5-year survival rate below
9%, and novel, more effective therapeutics for PDAC remain an
important unmet need [38e40].
2. Chemistry
The new imidazothiadiazole derivatives 12e14 were efficiently
synthesized following the synthetic route described in Scheme 1.
The commercially available indole-3-carbonitrile 9a and the de-
rivatives 9b-e, prepared by reaction of the appropriate 1H-indoleyrimidine-triazole hybrids 2, pyrazole-benzofuran hybrids 3.
Fig. 2. Chemical structures of the anticancer compounds 4e6.
Fig. 3. Hybrid compound 7 obtained by combining the two bioactive scaffolds indole and imidazothiadiazole.
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ation for obtaining the corresponding 1-methyl-1H-indole-3-
carbonitriles 10a-e [16]. The 5-(1H-indol-3-yl)-1,3,4-thiadiazol-2-
amines 11a-j were obtained in excellent yields (92e100%) by treat-
ing the proper derivatives 9a-e or 10a-e with thiosemicarbazide.
The 1,3,4-thiadiazol-2-amines 11a-j underwent a reaction with
the appropriate a-bromoacetyl compounds in refluxing ethanol to
give the hydrobromide derivatives 12a-r. Some of such hydro-
bromides, 12a,b,d,e,f,h, were isolated as pure compounds (yields
55e68%) and were characterized without further purifications.
Instead, hydrobromides 12c,g,i,j were treated with saturated
aqueous NaHCO3 solution producing the corresponding free bases
13 which were purified by column chromatography providingspecimens with suitable analytical and spectral data (yields
58e80%).
Finally, the free bases 13k-r, prepared through the treatment of
the corresponding hydrobromides 12 with saturated aqueous
NaHCO3 solution, were subjected to a reaction of formylation using
standard Vilsmeier conditions to give the imidazo [2,1-b] [1,3,4]
thiadiazole derivatives 14k-r (yields 70e90%) (Table 1).
Data on physicochemical properties of the compounds are re-
ported in the Supplementary results and Supplementary
Tables 1e2.
Reagents and conditions: i) CH3CN, CSI, 0 C, 2 h, then DMF, 0 C,
1.5 h (98e100%); ii) DMF, (CH3O)2CO, K2CO3, 130 C, 3.5 h
(98e100%); iii) trifluoroacetic acid, thiosemicarbazide, 60 C, 3.5 h
Table 1
New 3-(imidazo [2,1-b] [1,3,4]thiadiazol-2-yl)-1H-indole derivatives 12e14.
Comp R R1 R2 Yield
12a H H tiophen-3-yl 57%
12b H CH3 tiophen-3-yl 55%
12d Br CH3 tiophen-3-yl 68%
12e Cl H tiophen-3-yl 63%
12f Cl CH3 tiophen-3-yl 68%
12h F CH3 tiophen-3-yl 58%
13c Br H tiophen-3-yl 58%
13g F H tiophen-3-yl 80%
13i OCH3 H tiophen-3-yl 58%
13j OCH3 CH3 tiophen-3-yl 70%
14k H H C6H5 71%
14l H CH3 C6H5 91%
14m H H 4-F-C6H4 81%
14n H H 3OCH3eC6H4 60%
14o H H 2,5-OCH3-C6H3 82%
14p H CH3 2,5-OCH3-C6H3 70%
14q H H 4-NO2-C6H4 75%
14r Br H 2,5-OCH3-C6H3 90%
S. Cascioferro et al. / European Journal of Medicinal Chemistry 189 (2020) 1120884(98e100%); iv) anhydrous ethanol, reflux, 24 h (42e80%); v)
NaHCO3 saturated aqueous solution (58e80%); vi) POCl3, DMF,
0e5 C, then compound 13, DMF, 70 C, 5 h.3. Results and discussion
3.1. Antiproliferative activity
The newly synthesized imidazo [2,1-b] [1,3,4]thiadiazoles
12a,b,d,e,f,h, 13c,g,i,j and 14k,l,n,o,p were submitted to the Na-
tional Cancer Institute (NCI; Bethesda, MD) for the pharmacological
evaluation of their antitumor activity. They were initially pre-
screened according to the NCI protocol at one-dose of 10 mM on
the full panel of 60 human cancer cell lines derived from 9 cancer
cell types and grouped into disease subpanels including leukemia,
non-small cell lung, colon, central nervous system, melanoma,Scheme 1. Synthesis of 3-(imidazo [2,1-b] [1,3,4]tovarian, renal, prostate, and breast cancers. The 12a and 12h de-
rivatives were selected for further screening at five concentrations
at 10-fold dilution (104-108 M) on the full panel. As shown in
Table 2, both derivatives have interesting in vitro anticancer activity
with GI50 values ranging frommicromolar to sub-micromolar level,
i.e., 0.23e11.4 mM, and 0.29e12.2 mM, respectively (Table 2).
In order to expand the NCI panel, we evaluated the in vitro
antiproliferative activity of the compounds 12a,b,d,e,f,h, 13c,g,i,j
and 14k-r on a panel of PDAC cells, including SUIT-2, Capan-1 and
Panc-1, by Sulforhodamine-B (SRB) assay. PDAC is indeed broadly
chemoresistant tumor, with a 5-year survival rate below 9%, and
novel, more effective therapeutics for PDAC remain an important
unmet need.
A pre-screening assay was initially performed at concentrations
of 0.1, 1 and 16 mM.We then expanded the cytotoxicity test, using at
least 8 different concentrations (from 125 nM to 16 mM) on the
most promising compounds, in order to define more accurate half-
maximal inhibitory concentration (IC50) values. The compounds
12a,b,h and 13g exhibited remarkable antiproliferative activity on
all the preclinical models with IC50 values in the range from 0.85 to
4.86 mM (Table 3).
PDAC is notoriously resistant to chemotherapy or radiotherapy.
For several decades, gemcitabine monotherapy has been used as a
first-line treatment for metastatic PDAC and is still a cornerstone of
PDAC treatment in all stages of this disease. However, this drug has
limited clinical effects caused by primary PDAC resistance, as well
as by the development of resistance within a few weeks from
treatment initiation [41]. Therefore, new therapeutic agents should
be tested for their ability to circumvent gemcitabine chemo-
resistance. For this reason, we assessed the cytotoxic activity of the
compounds 12a,b,h and 13g in the Panc-1R cells, a gemcitabine-
resistant sub-clone obtained by continuous incubation of Panc-1
with 1 mM of the drug [41]. Notably, all these compounds showed
antiproliferative activity against Panc-1R, with IC50 ranging from
2.2 ± 0.37 mM (compound 12b) to 3.9 ± 0.25 mM (compound 13g) as
reported in Fig. 4.hiadiazol-2-yl)-1H-indole derivatives 12e14.
Table 2
GI50 and TGI of the compounds 12a and 12h.a
Panel/Cell line 12a 12h
GI50 (mM) TGI (mM) GI50 (mM) TGI (mM)
Leukemia
CCRF-CEM 2.19 27.2 2.54 >100
HL-60 (TB) 0.76 20.9 1.34 15.5
K-562 0.38 39.9 0.45 >100
RPMI-8226 1.47 15.4 3.01 27
Non-Small Cell Lung Cancer
A549/ATCC 1.72 >100 2.85 99.5
EKVX 1.99 >100 2.51 >100
HOP-62 1.58 39.9 1.92 23.1
HOP-92 5.46 >100 12.2 76.9
NCIeH226 9.94 >100 4.56 35.8
NCIeH23 4.47 >100 3.82 >100
NCIeH322 M 4.85 52.7 4.71 >100
NCIeH460 0.57 >100 1.73 17.1
NCIeH522 0.75 >100 1.62 24.5
Colon Cancer
HCC-2998 2.99 26.7 5.64 33.9
HCT-116 0.63 70.6 2.04 26.4
HCT-15 0.49 15.6 0.61 >100
HT29 0.41 10.2 0.48 14.8
KM12 0.50 10.5 1.04 >100
SW-620 0.43 >100 0.48 >100
CNS Cancer
SF-268 3.84 >100 6.58 >100
SF-295 1.74 6.44 2.24 9.39
SF-539 1.49 4.60 2.18 7.54
SNB-19 2.56 >100 3.44 >100
SNB-75 0.45 8.09 1.29 6.45
U251 1.21 17 2.76 17.9
Melanoma
MALME-3M 10.4 36.9 1.81 31.6
M14 0.75 15.8 1.05 >100
MDA-MB-435 0.23 0.68 0.29 1.13
SK-MEL-2 1.08 23.8 1.59 7.29
SK-MEL-28 4.74 44.0 7.23 >100
SK-MEL-5 0.71 15.1 1.80 12.9
UACC-257 11.4 98.3 7.90 >100
UACC-62 0.74 18.7 1.93 >100
Ovarian Cancer
IGROV1 1.79 >100 1.93 >100
OVCAR-3 0.92 9.02 2.06 9.67
OVCAR-4 4.42 >100 5.77 >100
OVCAR-5 4.27 76.4 8.24 84.4
OVCAR-8 2.72 >100 4.53 >100
NCI/ADR-RES 0.56 >100 0.99 19.1
SK-OV-3 2.80 82.7 3.47 70.9
Renal Cancer
786e0 3.06 >100 7.62 52.3
A498 5.97 23.6 4.09 50.0
ACHN 3.23 52.5 3.39 86.8
CAKI-1 1.00 >100 2.42 57.4
RXF 393 2.05 50.0 1.59 5.73
SN12C 1.15 >100 4.71 >100
TK-10 5.21 33.5 4.92 19.4
UO-31 1.71 >100 1.72 >100
Prostate Cancer
PC-3 2.07 >100 3.19 >100
DU-145 2.86 >100 3.67 31.6
Breast Cancer
MCF7 1.17 20.2 0.83 30.0
MDA-MB-231/ATCC 1.08 7.88 3.23 30.6
HS 578T 2.65 >100 2.34 13.4
BT-549 2.87 31.7 5.54 77.4
MDA-MB-468 2.92 27.8 1.44 5.47
a Data obtained from the NCI in vitro disease-oriented human tumor cell line
screen. [b] GI50: concentration that inhibit 50% net cell growth. [c] TGI total growth
inhibition.
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modifications, including splicing and phosphoproteomics aberra-
tions [42,43], underlying the molecular mechanisms of
gemcitabine-resistance, and further studies will be carried out to
identify how our new compounds counteract these mechanisms.
Moreover, the compounds 12a,b,h and 13g were tested on a pri-
mary patient-derived PDAC cell culture, PDAC-3 (Fig. 4B and C). This
cellular model was chosen since our previous studies showed that
its genetic and histological features were similar to the original
tumor [44]. In order to maintain the original characteristics of the
primary tumor, particularly from the genetic point of view, these
cells have been kept in culture only for a few passages. As shown in
Fig. 4B the new imidazothiadiazoles maintained their anti-
proliferative activity on PDAC-3 cells, with IC50 values slightly
higher in comparison to the values reported on the previously
mentioned cancer cell lines. The phase contrast microscopy images
in Fig. 4C highlighted the antiproliferative activity of compounds
12a and 12b (central and right panel, respectively) compared to
untreated cells (left picture) after 72 h of the treatment.
Because of their remarkable antiproliferative activity the com-
pounds 12a,b,h and 13g were selected for following mechanistic
studies, in order to unravel the mechanisms underlying their
anticancer activity.
Despite compound 7 has shown interesting GI50 values against
all the tested cancer cell lines in the NCI screening, preliminary
biological evaluations of analogues 13k,l,n,p,r showed limited
antiproliferative activity [28]. We evaluated the citotoxicity of the
compounds 13m, 13o and 13q on SUIT-2, Capan-1 and Panc-1 but
the IC50 values were above 16 mM.
Finally, we performed additional experiments to evaluate the
in vitro cytotoxicity of the new compounds 12a and 12b against the
normal fibroblasts Hs27. The results of these experiments allowed
us to calculate the selectivity index (SI, IC50 non-tumor cell line/IC50
tumor cell line), which was 4.5 and 7.2 for compounds 12a and 12b,
respectively, and therefore our compounds have SI similar to
Gemcitabine and 5-fluorouracil and were regarded as highly cancer
selective compared to the primary pancreatic cells PDAC3
(Supplementary Table 3).3.2. Volume reduction of PDAC-3-derived tumor spheres
Two-dimensional cytotoxicity assay obviously provide a useful
method to screen libraries of compounds with high-throughput
efficiency, but they are not capable of resembling the complex ar-
chitecture and biology of solid tumors, which grow in three-
dimensions (3D) [45]. For this reason we evaluated two of our
most promising compounds (emerging from monolayer assay) on
3D spheroids of PDAC-3 cells. These primary cultures are indeed
able to form spheroids that are more representative of the aggre-
gation of tumor cells in vivo, as also reported in our previous
studies [46].
We treated spheroids with compounds 12a and 12b after 3 days
of growth, at 5-times the IC50, and we took a picture which
represent the Day 1. Then the treatment was repeated every four
days (Day 5 and Day 8) and pictures were taken immediately before
that (Fig. 5A).
Reduction of the size of spheroids was calculated by measuring
their area with ImageJ. As shown in Fig. 5B, after five, but consid-
erably more after eight days, both compounds clearly showed their
ability to hinder the spheroids formation. This reduction is shown
as the fold-change between treated spheroids compared to the
controls and was statistically significant (p-value < 0.0001).
Therefore, these two compounds retained their activity in a 3D
model.
Table 3
Antiproliferative activity of compounds 12a,b,d,e,f,h, 13c,g,i,j and 14k-r on SUIT-2, Capan-1 and Panc-1 cell lines.
IC50a (mM) ± SEMb
Cell lines
Comp SUIT-2 Capan-1 Panc-1
12a 0.85 ± 0.018 1.19 ± 0.06 1.70 ± 0.20
12b 0.99 ± 0.078 1.35 ± 0.04 1.69 ± 0.10
12d >16 >16 >16
12e >16 >16 >16
12f >16 >16 >16
12h 1.78 ± 0.017 1.93 ± 0.25 2.37 ± 0.028
13c >16 >16 >16
13g 2.16 ± 0.039 4.52 ± 0.48 4.86 ± 0.5
13i >16 >16 >16
13j >16 >16 >16
14k 9.56 ± 0.34 10.5 ± 0.21 12.41 ± 0.16
14l >16 >16 >16
14m 7.93 ± 0.23 8.83 ± 0.17 10.53 ± 037
14n 11.49 ± 0.36 >16 >16
14o 13 ± 1.13 >16 >16
14p 12.49 ± 0.18 5.73 ± 0.086 >16
14q 5.32 ± 0.29 6.1 ± 0.019 3.61 ± 0.4
14r 8.7 ± 0.20 8.24 ± 0.08 10.56 ± 0.11
gemcitabine 0.01 ± 0.001 0.02 ± 0.001 0.15 ± 0.01
5-fluorouracil 0.91 ± 0.15 0.47 ± 0.13 4.3 ± 0.42
a The values are means ± SEM of three separate experiments.
b SEM: Standard Error of the Mean.
Fig. 4. Representative growth curves of Panc-1R (A) and PDAC-3 (B) cells treated with the compounds 12a,b,h and 13g (from 0.125 to 16 mM). Points, mean values obtained from
three independent experiments; bars, SEM. (C) Representative pictures of PDAC-3 cells after 72 h from the treatment at concentration of IC50 value. Left panel: untreated cells;
central panel: cells treated with compound 12a; right panel: cells treated with compound 12b. Original magnification 20X. (D) IC50 values of compounds 12a,b,h and 13g on
gemcitabine-resistant and primary PDAC-3 cells (aThe values are means of three separated experiments. bSEM: Standard Error Mean).
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Next to the lack of clinically relevant improvement in effective
treatments, the highmetastatic potential of PDAC is one of themain
causes for the poor outcome of this disease [36]. The ability of the
compounds 12a and 12b to inhibit themigratory behaviour of PDAC
cells was investigated by scratch wound-healing assays on SUIT-2,
Capan-1, Panc-1, Panc-1R and PDAC-3 cell lines.
Briefly, 5  104 cells/well were seeded into 96-well flat-bottomplates in a volume of 100 mL and incubated for 24 h to create a
monolayer. The scratches in themiddle of thewells were created by
scraping with a specific tool with needles. The cells were then
treated with the compounds using 4x IC50 concentrations. These
concentrations were chosen after preliminary experiments
demonstrating that the exposure for 24 h did not result in pro-
apoptotic or necrotic effects. The wound closure was monitored
by phase-contrast microscopy and the pictures were captured
immediately after scratch (T ¼ 0), and at 4, 8, 20 and 24 h from the
Fig. 5. Size reduction of PDAC-3 spheroids treated with compounds 12a and 12 b at 5-times the IC50 (i.e. 8.5 mM). (A) Representative pictures of PDAC-3 spheroids exposed to 12a
and 12b, taken at day 1 of treatment, and after 5 and 8 days with an automated phase-contrast microscope. (B) Fold-change, corrected for control, of the spheroids size, at Day 1, Day
5 and Day 8. p-values were determined by Two-way ANOVA followed by Tukey’s multiple comparisons test, **** ¼ p < 0.0001. The values were obtained taking into account the
mean values of the areas of at least ten different spheroids.
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induced a remarkable reduction of cell migration rate in Panc-1R
and SUIT-2 cell lines. The scratch area (mm2) was already wider in
the treated cells compared to the untreated Panc-1R cells after 8 h
of treatment. After 24 h from the beginning of the treatment we
observed a reduction of the cell migration with a fold-change value
of approximately 4 in both cell lines, SUIT-2 and Panc-1, treated
with compounds 12a and 12b (Fig. 6A,B). Statistical analyses
revealed that these differences were significant, compared to the
respective controls (i.e., untreated cells) in both cell lines.
In particular, compared to untreated cells (set at 100%), the
percentages of migration in cells treated with the compounds 12aFig. 6. Modulation of the migration rate in Panc-1R and SUIT-2 cells treated with the compo
SUIT-2 (B) cells were determined by taking into consideration at least four scratch areas
**p < 0.01, *p < 0.05. (C-D) Percentages of migration monitored over time (0, 4, 8, 20 an
concentration 4x IC50. Points, mean values obtained from the means of at least three differ
microscope at 0, 8 and 20 h on Panc-1R cells. Original magnification 5X.and 12b were of 33.3% and 32%, respectively, in Panc-1R (Fig. 6C),
and 34.9% and 41%, respectively, in SUIT-2 (Fig. 6D) after 24 h from
the start of the treatment. The anti-migratory activity was also
evident in Capan-1 and Panc-1 cells for which we observed similar
statistically significant results, with migration rates between 50%
and 60% (Fig. 7AeC and Fig. 7AeD). Finally, as shown in the Sup-
plementary data Fig. 1A, we detected lower migration rates (64%
and 71%, respectively) compared to the control (set at 100%) also in
the primary PDAC-3 cells treated with the compounds 12a and 12b.
Overall, these data highlighted the ability of our compounds to
significantly reduce the rate of cell migration on all the PDAC pre-
clinical models.unds 12a and 12 b at concentration of 4x IC50. (A-B) Fold-changes in Panc-1R (A) and
. All the P values were calculated with Student’s t-test. ****p < 0.0001, ***p < 0.001,
d 24 h) of Panc-1R (C) and SUIT-2 (D) cells treated with compound 12a and 12 b at
ent scratch areas. (E) Representative images of the wounds closure captured with the
Fig. 7. (A-D) Percentage of migration monitored over time (0, 4, 8, 20 and 24 h) of Capan-1 (A-B) and Panc-1 (C) cells treated with the compounds 12a and 12 b at concentrations of
4x IC50. Points, mean values obtained from the means of at least three different scratch areas. (D) (Table) List of P values that were calculated with Student’s t-test. ****p < 0.0001,
***p < 0.001, **p < 0.01, *p < 0.05, ns ¼ not significant.
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assessed by qRT-PCR, western blot and gelatine zymography
It is well known that epithelial-to-mesenchymal transition
(EMT) events are essential for embryonic development and other
physiological events, such as the response to several injuries.
During EMT, epithelial cells undergo changes in their phenotypic
tracts through the loss of polarity, cell-cell adhesion and extracel-
lular matrix, and they acquire mesenchymal features including
motility and invasiveness [47]. Several transcription factors within
the cellular microenvironment regulate the expression of epithelial
and mesenchymal marker genes, among which the most important
include the zinc finger transcription factors SNAIL1 and SNAIL2,
potent epithelial repressors belonging to the SNAIL superfamily, E-
cadherin (CDH1) and N-cadherin (CDH12), calcium-dependent cell
adhesion molecules, vimentin (VIM), type III intermediate filament
(IF) protein typically expressed in mesenchymal cells, and finally,
the matrix metalloproteinases (MMPs), enzymes involved in the
breakdown of extracellular matrix [48]. Remarkably, their dysre-
gulation induces a transition from the physiological function to the
pathological one, including mechanisms underlying the origin and
progression of tumors and tissue fibrosis [49]. The loss of CDH1
expression is considered the hallmark of EMTs in cancer and
recently, SNAIL1 and SNAIL2 have been identified as the major
determinants for the repression of its transcription through the
direct binding to the E-cadherin E-box promoter [50e52]. Simul-
taneously, the gain of mesenchymal markers, such as VIM, CDH12,
MMPs and others occur [53]. In PDAC, these genes contribute to a
crucial network of signalling pathways that contribute to the irre-
versible change of cell phenotype, both inmetastasis and resistance
to the chemotherapy [54]. Because of their outstanding effects
against PDAC cell migration, we assessed the influence of the imi-
dazothiadiazole derivatives 12a and 12b on these EMTs key regu-
lator expression, in SUIT-2, Capan-1 and Panc-1 cells, using RT-qPCR, Western blot and gelatine zymography analyses. Capan-1
and SUIT-2 cells were selected for these experiments because
preliminary analyses of the housekeeping protein GAPDH showed
that using lysates of these cells the Western blot images were not
“saturated” and were kept in the linear range (as revealed by
exposing blots to increasing times and drawing a plot of intensity
and time exposure). RT-qPCR reactions were performed in order to
evaluate themodulation of themRNA expression of SNAIL1, SNAIL2,
CDH1, CDH12. Briefly, SUIT-2 and Capan-1 cells (2.5  105/well)
were seeded into 6-well plates and incubated for 24 h to form a
confluent monolayer. Then they were treated with the compounds
12a and 12 b at concentrations of 5x IC50. After 24 h, the cells were
harvested using TRIzol, and we extracted the total RNA, which was
used to synthesize, by reverse transcription, the cDNA for the PCR
reactions. The expression levels were normalized to those of the
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) house-
keeping gene, whose expression was constant in all cells, as
described previously [55]. As shown in Fig. 8A and B, the com-
pounds 12a and 12b affected the genes leading EMTs. In both cell
lines the mRNA levels of SNAIL1 and SNAIL2 were increased from
1.5 to approximately 1.9 fold compared to the GAPDH in the control
cells, suggesting a low amount of protein expression and conse-
quently, due to a negative feedback mechanism, CDH1 protein
expression was upregulated, as reported in the Western blot anal-
ysis (Fig. 8C and D, Fig. 8G and Supplementary data Fig. 2). Instead,
the protein expression of VIM and MMP2 were significantly
reduced. Finally, CDH12 protein expression did not noticeably
change compared to the control.
Furthermore, considering the pivotal role of MMPs in tumor
invasion, through degradation of extracellular matrix components,
we evaluated the effect of the compounds 12a and 12b on the
proteolytic activity of MMP2 and MMP9 by using specific gelatine
zymography assays. These assays showed a significant decrease of
the activity of MMP2 and MMP9 isolated from SUIT-2 and Capan-
Fig. 8. SNAIL1, SNAIL2, CDH1 and CDH12 mRNA expressions in SUIT-2 (A) and Capan-1 (B) cells treated with the compounds 12a and 12 b at 5x IC50 for 24 h. The expression levels
were determined by RT-qPCR and the results were obtained by the delta-delta Ct (cycle threshold) analysis. The experiments were conducted in duplicates and the values are shown
as means ± SD. (C-D) SNAIL1, SNAIL2, CDH1, CDH12, VIM and MMP2 protein levels expression in SUIT-2 (C) and Capan-1 (D) cells treated with compounds 12a and 12b. The protein
levels were determined after 24 h of treatment at concentration 5x IC50 value by densitometric analysis of the Western Blot performed using ImageJ. All the P values were
determined by Tukey’s multiple comparisons test. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. (E-F) Gelatine zymography analysis of media from SUIT-2 and Capan-1 cells
incubated with serum-free medium for 24 h. The enzymatic activity of MMP2 and MMP9 was determined by densitometric analysis. The cells were treated with the compounds 12a
and 12 b at concentration 5x IC50 value for 24 h ****p < 0.0001, ***p < 0.001. (G) Representative image of CDH1 expression determined by Western blot analysis in Capan-1 cells
treated with the compounds 12a and 12 b at 5x IC50 concentrations after 24 h.
S. Cascioferro et al. / European Journal of Medicinal Chemistry 189 (2020) 112088 91 cells exposed to the compounds. In particular, the activities of the
MMP2 andMMP9 enzymes were decreased by about 50% after 24 h
of treatment compared to the control (Fig. 8E and F). However, as
shown in the Supplementary data Fig. 3, the areas of lysis created
by the proteolytic activities of both enzymes isolated from Panc-
1 cells treated with compounds 12a and 12bwere not significantly
wider compared to the control.
3.5. Profiling of inhibition of kinase activity
To investigate the potential mechanism of action of ourcompounds, we performed a high-throughput analysis with the
Pamgene tyrosine kinase peptide substrate array (PamChip). The
PamChip consists of 4 identical arrays, each of which contains 144
peptide sequences immobilized on a porous ceramic membrane
(Fig. 9A). Each of these sequences harbours one or more phos-
phorylation sites, derived from literature or computational pre-
dictions. Finally, specific fluorescently labelled anti-phospho
antibodies are used to detect the amount of phosphorylated protein
by tyrosine kinases from our samples.
The compound 12b significantly inhibited the phosphorylation
of 45 peptide substrates in SUIT-2 cells, and we visualized on
Fig. 9. (A) Representative images of pictures taken at the end point of the control array (left) and the treated array (right). (B) Network visualization obtained with Cytoscape of the
significant proteins containing differentially phosphorylated peptides, color legend indicates the significance level of each protein. (C) Barplot of PTK2 phosphorylation in the
control vs treated with 5x IC50 of 12b. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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teins containing the phosphorylated peptides. Notably, PTK2/FAK
emerged as an important hub between those proteins (Fig. 9B). In
particular, the phosphorylation of PTK2/FAK showed amore than 2-
fold inhibition after treatment with compound 12b, with FDR <0.01
(Fig. 9C). This result prompted us to validate the inhibition of
phosphorylation of PTK2/FAK as one of the possible mechanisms of
action of our compound, using a specific ELISA assay, as detailed in
the following paragraphs.
3.6. Inhibition of PTK2/FAK as assessed by ELISA
The focal adhesion kinase (FAK), also known as protein tyrosine
kinase 2 (PTK2), is a downstream non-receptor tyrosine kinase able
to mediate information from extracellular matrix into the cyto-
plasmatic compartment, through a linker with intracellular tails of
integrins [56]. FAK controls several cellular processes, including
survival, proliferation and motility. However, its overexpression is
correlated with many aspects of the tumorigenesis. For instance,
FAK regulates the development of metastasis, driving adhesion,
invasion and migration events. Furthermore, the translocation of
FAK in the nucleus induces the arrest of p53 activity and its
downstream gene transcription [57]. In PDAC, FAK coordinates
several signalling pathways involved in growth and metastasis
processes [58]. Notably, a recent study reported the ability of the
indole-3-carbinol to affect EMTs genes and reduce FAK mRNA
expression in MCF-7 cells [59]. Thereby, we conducted a quantita-
tive analysis by the Enzyme-Linked Immunosorbent Assay (ELISA)
to investigate whether our imidazothiadiazole compounds could
reduce FAK phosphorylation at tyrosine residue 397 (FAK [pY397]),
which is essential for the kinase activity of this protein. This assay
was carried out on lysates of SUIT-2, Capan-1 and Panc-1 cells
treated with compounds 12a and 12 b at concentrations of 5x IC50s
for 24 h. As shown in Fig. 10, these ELISA experiments showed a
reduction of p-FAK in all the PDAC cell lines, with fold-changevalues ranging from 0.4 to 0.5. Similar results were observed in
the Western blot analyses of the same compounds (Supplementary
Fig. 4). These results suggest that FAK is a target of our compounds
and might explain how they can then suppress FAK-driven migra-
tion, and growth in PDAC cells.
4. Conclusions
A new series of hybridmolecules,12a,b,d,e,f,h,13c,g,i,j and 14k-
r compounds bearing in the same structure the imidazo [2,1-b]
[1,3,4]thiadiazole and indole scaffolds were efficiently synthesized
and evaluated for their antiproliferative activity and mechanism of
action on a panel of PDAC cells, namely SUIT-2, Capan-1 and Panc-1.
Among the synthesized imidazothiadiazoles, compounds
12a,b,d,e,f,h, 13c,g,i,j and 14k,l,n,o,p were screened by the NCI on
the full panel of sixty human cancer cells at concentration of 10 mM.
Notably, compounds 12a and 12h displayed relevant anti-
proliferative activity eliciting GI50 values in the range frommicro-to
sub-micromolar levels. In addition, compounds 12b and 13g
considerably reduced PDAC cell proliferation in SUIT-2, Capan-1,
Panc-1, Panc-1R (gemcitabine-resistant) and in the primary cells
PDAC-3, growing as monolayers or as spheroids. Noteworthy,
compounds 12a,b,h and 13g are characterized by a thiophene ring
at position 6 of the imidazothiadiazole scaffold, suggesting the
importance of this ring for the pharmacological activity. However,
in order to confirm the role of aldehyde for the antiproliferative
activity future studies in 14a-j compounds are warranted.
Through wound-healing assays we found remarkably reduction
of cell migration in all the PDAC preclinical models when treated
with the most promising compounds 12a and 12b. These effects
might be explained by modulation of key regulators of EMT,
including E-cadherin and vimentin, as well as by the inhibition of
MMP-2/-9 activities. Finally, high-throughput analysis with kinase
arrays revealed a significant inhibition of the phosphorylation of 45
tyrosine kinases substrates, whose visualization on Cytoscape
Fig. 10. Inhibition of FAK/PTK2 phosphorylation by compounds 12a and 12b. Modulation of phosphorylated-FAK (pFAK) at tyrosine residue 397 by compounds 12a and 12b on
Panc-1 (A), Capan-1 (B) and SUIT-2 (C) cells. The amount of pFAK was measured in cell lysates after 24 h from the treatment with compounds 12a and 12 b at 5x IC50s. All the P
values were calculated with Student’s t-test, *p < 0.05.
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These results were validated using a specific ELISA assay, which
demonstrated the inhibition of phosphorylation of PTK2/FAK.
Altogether these results support the high potential of this type of
compounds against EMTand PTK2/FAK, which play a key role in the
aggressiveness of pancreatic cancer [55]. In order to support our
experimental findings we also investigated the molecular structure
of FAK. Unfortunately complete crystal structures of the molecule
are not available; e.g. the Tyr397 part is lacking in the published
structures, which may be due to the high flexibility of this region of




All melting points were taken on a Büchi-Tottoly capillary
apparatus and are uncorrected. IR spectra were determined in
bromoform with a Shimadzu FT/IR 8400S spectrophotometer. 1H
and 13C NMR spectra were measured at 200 and 50.0 MHz,
respectively, in DMSO‑d6 solution, using a Bruker Avance II series
200 MHz spectrometer. Column chromatography was performed
with Merck silica gel 230e400 mesh ASTM or with Büchi Sepacor
chromatography module (prepacked cartridge system). Elemental
analyses (C, H, N) were within ±0.4% of theoretical values and were
performed with a VARIO EL III elemental analyzer. The LC/HRMS
have been obtained on a Thermo Q-Exactive system equipped with
a Dionex 3000 chromatographic system.
5.1.1. Synthesis of 1H-indole-3-carbonitriles (9b-e)
A solution of the suitable indole 8 (5.10 mmol) in anhydrous
acetonitrile (4.5 mL) was treated dropwise with chlorosulfonyl
isocyanate (CSI) (0.44 mL, 5.10 mmol). The reaction mixture was
maintained at 0 C under stirring for 2 h, then, anhydrous dime-
thylformamide (DMF) (2.8 mL, 36.39 mmol) was slowly added and
the mixture was stirred at 0 C for 1.5 h. The resulting solution was
poured into crushed ice. The solid obtained was filtered and dried
(yields 98e100%). Analytical and spectroscopic data for compounds
9b-e are in agreement with those previously reported [60].
5.1.2. Synthesis of 1-methylindole-3-carbonitriles (10a-e)
To a solution of the suitable 3-cyanoindole 9 (7.03 mmol) in
anhydrous DMF (10 mL) 3.61 mmol of K2CO3 and dimethyl car-
bonate (1.8mL, 21.4mmol) were added and themixturewas heated
at 130 C for 3.5 h. After cooling (0e5 C), water and ice (25mL) wasslowly added under stirring. The oily suspension obtained was
extracted with diethyl ether (3  10 mL), the organic phase was
washed with water and brine, dried over Na2SO4 and the solvent
evaporated at reduced pressure to obtain the 3-cyano-1-
methylindoles 10 in excellent yields. Analytical and spectroscopic
data are in accordance to those reported in literature [16].
5.1.3. Synthesis of 5-(1H-indol-3-yl)-1,3,4-thiadiazol-2-amines
(11a-j)
A mixture of the suitable indole-3-carbonitrile 9a-e or 10a-e
(5 mmol), thiosemicarbazide (5 mmol) and trifluoroacetic acid
(5 mL) was heated under stirring at 60 C for 3.5 h. The reaction
mixture was then poured into ice and neutralized with NaHCO3
saturated solution. The solid obtained was filtered off, washed with
water, cyclohexane and diethyl ether to give 5-(1H-indol-3-yl)-
1,3,4-thiadiazol-2-amines 11a-j in excellent yields. Analytical and
spectroscopic data for the derivatives 11a-f are in accordance to
those reported in literature [16].
5.1.3.1. 5-(5-Methoxy-1H-indol-3-yl)-1,3,4-thiadiazol-2-amine (11g).
Light yellow solid. Yield: 98%, m.p. 216e217 C IR: 3604 (NH), 3558
(NH2) cm 1; 1HNMR (200 MHz, DMSO‑d6) d: 3.79 (3H, s, CH3), 6.88
(1H, dd, J ¼ 2.4, 8.8 Hz, AreH), 7.39 (1H, d, J ¼ 8.8 Hz, AreH), 7.53
(1H, d, J ¼ 2.3 Hz, AreH), 8.02 (1H, s, AreH), 8.58 (2H, bs, NH2),
12.07 (1H, bs, NH). 13C NMR (50 MHz, DMSO‑d6) d: 55.2 (q), 101.9
(d), 105.7 (s), 112.9 (d), 113.0 (d), 124.4 (s), 128.7 (d), 131.5 (s), 152.2
(s), 154.7 (s), 166.5 (s). Anal. Calcd for C11H10N4OS (MW: 246.29): C,
53.64; H, 4.09; N, 22.75. Found: C, 53.72; H, 4.16; N, 22.98.
5.1.3.2. 5-(5-Methoxy-1-methyl-1H-indol-3-yl)-1,3,4-thiadiazol-2-
amine (11h). Light yellow solid. Yield: 99%, m.p. 205e206 C IR:
3381 (NH2) cm 1; 1HNMR (200 MHz, DMSO‑d6) d: 3.80 (6H, s, CH3,
OCH3), 6.90 (1H, dd, J ¼ 2.5, 8.8 Hz, AreH), 7.13 (2H, s, NH2), 7.41
(1H, d, J ¼ 8.9 Hz, AreH), 7.61 (1H, d, J ¼ 2.4 Hz, AreH), 7.81 (1H, s,
AreH). 13C NMR (50 MHz, DMSO‑d6) d: 32.8 (q), 55.3 (q), 102.3 (d),
106.0 (s), 111.2 (d), 112.5 (d), 124.9 (s), 130.7 (d), 132.0 (s), 152.2 (s),
154.6 (s), 165.4 (s). Anal. Calcd for C12H12N4OS (MW: 260.31): C,
55.37; H, 4.65; N, 21.52. Found: C, 55.42; H, 4.80; N, 21.78.
5.1.3.3. 5-(5-Fluoro-1H-indol-3-yl)-1,3,4-thiadiazol-2-amine (11i).
Light yellow solid. Yield: 98%, m.p. 257 C IR: 3609 (NH), 3461 (NH2)
cm 1; 1HNMR (200 MHz, DMSO‑d6) d: 7.03e7.12 (1H, m, AreH),
7.33e750 (3H, m, AreH, NH2), 7.80 (1H, dd, J ¼ 2.5, 10.0 Hz, AreH),
7.95 (1H, s, AreH), 11.79 (1H, s, NH). 13C NMR (50MHz, DMSO‑d6) d:
105.4 (d, J ¼ 24 Hz), 107.4 (s, J ¼ 4.5 Hz), 110.7 (d, J ¼ 25.5 Hz), 113.1
(d, J ¼ 10 Hz), 124.4 (s, J¼ 11 Hz), 128.6 (d), 130.1 (s), 152.0 (s), 159.9
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3.01; N, 23.92. Found: C, 51.38; H, 3.25; N, 24.12.
5.1.3.4. 5-(5-Fluoro-1-methyl-1H-indol-3-yl)-1,3,4-thiadiazol-2-
amine (11j). Light orange solid. Yield: 98%, m.p. 183 C. IR: 3471
(NH2) cm 1; 1HNMR (200 MHz, DMSO‑d6) d: 3.85 (3H, s, CH3),
7.12e7.21 (1H, m, AreH), 7.59 (1H, dd, J ¼ 4.4, 9.9 Hz, AreH), 7.76
(2H, dd, J ¼ 2.5, 9.8 Hz, AreH), 8.10 (2H, s, NH2). 13C NMR (50 MHz,
DMSO‑d6) d: 33.14 (q), 105.4 (s), 105.5 (d, J ¼ 24 Hz), 110.9 (d,
J¼ 26 Hz),112.0 (d, J¼ 9.5 Hz),124.3 (s),124.5 (s),133.1 (d),151.4 (s),
155.7 (s). Anal. Calcd for C11H9FN4S (MW: 248.28): C, 53.21; H, 3.65;
N, 22.57. Found: C, 53.38; H, 3.88; N, 22.72.
5.1.4. General procedure for the synthesis of 3-(6-phenylimidazo
[2,1-b] [1,3,4]thiadiazol-2-yl)-1H-indole derivatives (12 and 13)
A mixture of 5-(1H-indol-3-yl)-1,3,4-thiadiazol-2-amine 11a-j
(0.92mmol) and the suitable a-bromoacetyl derivative (0.92mmol)
in 40 mL of anhydrous ethanol was stirred at reflux for 24 h. After
cooling at room temperature the desired product 12was filtered off
and washed with cold ethanol.
Derivatives 12a,b,d-f,h were isolated as pure compounds and
were characterized without further purifications. Whereas, com-
pounds 12c,g,i,j were treated with saturated aqueous NaHCO3 so-
lution to give the corresponding free bases 13 which were purified
by silica gel column chromatography eluting by petroleum ether:-
ethyl acetate, 1:1. Analytical and spectroscopic data for the de-
rivatives 12k-r are in accordance to those reported in literature [16].
5.1.4.1. 3-[6-(Thiophen-3-yl)imidazo[2,1-b] [1,3,4]thiadiazol-2-yl]-
1H-indole hydrobromide (12a). White solid, yield: 57%, m.p.
288e289 C, IR cm1: 3630 (NH), 3458 (NH). 1HNMR (200 MHz,
DMSO‑d6) d: 7.27e7.34 (2H, m, 2xAr-H), 7.54e7.59 (2H, m, 2xAr-H),
7.68 (1H, dd, J ¼ 2.9, 5.0 Hz, AreH), 7.89 (1H, dd, J ¼ 1.1, 2.8 Hz,
AreH), 8.16 (1H, dd, J ¼ 2.8, 6.2 Hz, AreH), 8.42 (1H, d, J ¼ 3.0 Hz,
AreH), 8.71 (1H, s, AreH), 10.63 (1H, bs, NH), 12.24 (1H, s, NH). 13C
NMR (50 MHz, DMSO‑d6) d: 106.06 (s), 110.68 (d), 112.62 (d), 120.30
(d), 120.52 (d), 121.65 (d), 123.31 (d), 123.71 (s), 125.47 (d), 127.24
(d), 130.00 (d), 133.78 (s), 136.70 (s), 139.17 (s), 142.45 (s), 158.13 (s).
Anal. Calcd for C16H11BrN4S2 (MW: 403.32): C, 47.65; H, 2.75; N,
13.89. Found: C, 47.74; H, 2.83; N, 13.95. LC-HRMS: 323.04979 m/z.
5.1.4.2. 1-Methyl-3-[6-(thiophen-3-yl)imidazo[2,1-b] [1,3,4]thiadia-
zol-2-yl]-1H-indole hydrobromide (12b). Greenish yellow solid,
yield: 55%, m.p. 317e318 C, IR cm1: 2650 (NH). 1HNMR (200MHz,
DMSO‑d6) d: 3.91 (3H, s, CH3), 6.50 (1H, bs, NH), 7.32e7.41 (2H, m,
2xAr-H), 7.55 (1H, d, J ¼ 4.9 Hz, AreH),7.61e7.66 (2H, m, 3xAr-H),
7.81 (1H, d, J ¼ 2.4 Hz, AreH), 8.16 (1H, dd, J ¼ 2.4, 6.2 Hz, AreH),
8.38 (1H, s, AreH), 8.60 (1H, s, AreH). 13C NMR (50 MHz, DMSO‑d6)
d: 33.14 (q), 99.50 (s), 105.39 (s), 110.30 (d), 111.01 (d), 119.59 (d),
120.44 (s), 121.77 (d), 123.23 (d), 124.06 (s), 125.53 (d), 126.74 (d),
132.95 (s),133.28 (d),135.53 (s),137.25 (s),141.09 (d). Anal. Calcd for
C17H13BrN4S2 (MW: 417.35): C, 48.92; H, 3.14; N, 13.42. Found: C,
48.85; H, 3.22; N, 13.51. LC-HRMS: 337.05688 m/z.
5.1.4.3. 5-Bromo-1-methyl-3-[6-(thiophen-3-yl)imidazo[2,1-b]
[1,3,4]thiadiazol-2-yl]-1H-indole hydrobromide (12d). Whitish solid,
yield: 68%, m.p. 318e319 C, IR cm1: 2697e2500 (NH). 1HNMR
(200 MHz, DMSO‑d6) d: 3.87 (3H, s, CH3), 7.43e7.68 (4H, m, AreH),
7.81e7.83 (1H, m, AreH), 8.24 (1H, d, J ¼ 1.76 Hz, AreH), 8.38 (1H,
bs, NH), 8.43 (1H, s, AreH), 8.69 (1H, s, AreH). 13C NMR (50 MHz,
DMSO‑d6) d: 33.39 (q), 104.55 (s), 110.72 (d), 113.26 (d), 114.60 (s),
120.41 (d), 122.63 (d), 125.38 (d), 125.49 (s), 125.80 (d), 127.21 (d),
133.90 (s), 134.58 (d), 136.01 (s), 139.42 (s), 142.21 (s), 157.02 (s).
Anal. Calcd for C17H12Br2N4S2 (MW: 496.24): C, 41.15H, 2.44; N,
11.29. Found: C, 41.22; H, 2.52; N, 11.41. LC-HRMS: 416.96634 m/z.5.1.4.4. 5-Chloro-3-[6-(thiophen-3-yl)imidazo[2,1-b] [1,3,4]thiadia-
zol-2-yl]-1H-indole hydrobromide (12e). Whitish solid, yield: 63%,
m.p. 276e277 C, IR cm1: 3285 (NH), 3168 (NH). 1HNMR
(200 MHz, DMSO‑d6) d: 7.32 (1H, d, J ¼ 2.1 Hz, AreH), 7.52e7.68
(3H, m, AreH), 7.83 (1H, m, AreH), 8.15 (1H, d, J ¼ 1.9 Hz, AreH),
8.46 (1H, d, J ¼ 2.9 Hz, AreH), 8.71 (1H, s, AreH), 9.19 (1H, bs, NH),
12.37 (1H, s, NH). 13C NMR (50MHz, DMSO‑d6) d: 92.15 (s), 99.49 (s),
106.10 (s), 110.43 (d), 114.24 (d), 119.58 (d), 120.27 (d), 121.37 (s),
123.35 (d), 124.74 (s), 125.80 (d), 126.17 (s), 126.67 (d), 131.35 (d),
134.16 (s), 135.22 (s). Anal. Calcd for C16H10BrClN4S2 (MW: 437.76):
C, 43.90; H, 2.30; N, 12.80. Found: C, 43.99; H, 2.41; N, 12.91. LC-
HRMS: 357.00452 m/z.5.1.4.5. 5-Chloro-1-methyl-3-[6-(thiophen-3-yl)imidazo[2,1-b]
[1,3,4]thiadiazol-2-yl]-1H-indole hydrobromide (12f). Whitish solid,
yield: 68%, m.p. 324e325 C, IR cm1: 2625e2496 (NH). 1HNMR
(200 MHz, DMSO‑d6) d: 3.87(3H, s, CH3), 7.36 (1H, d, J ¼ 2.0 Hz
AreH), 7.51 (1H, m, J¼ 4.5 Hz AreH), 7.60e7.68 (2H, m, AreH), 7.82
(1H, d, J ¼ 1.8 Hz, AreH), 8.07 (1H, d, J ¼ 1.9 Hz, AreH), 8.45 (1H, s,
AreH), 8.64 (1H, bs, NH), 8.68 (1H, s, AreH). 13C NMR (50 MHz,
DMSO‑d6) d: 33.41 (q), 104.61 (s), 110.72 (d), 112.84 (d), 119.60 (d),
120.50 (d), 123.24 (d), 124.87 (s), 125.38 (d), 126.61 (s), 127.23 (d),
133.73 (s), 134.73 (d), 135.75 (s), 139.26 (s), 142.19 (s), 157.10 (s).
Anal. Calcd for C17H12BrClN4S2 (MW: 451.79): C, 45.19; H, 2.68; N,
12.40. Found: C, 45.25; H, 2.74; N, 12.45. LC-HRMS: 371.02017 m/z.5.1.4.6. 5-Fluoro-1-methyl-3-[6-(thiophen-3-yl)imidazo[2,1-b]
[1,3,4]thiadiazol-2-yl]-1H-indole hydro-bromide (12h). White solid,
yield: 58%, m.p. 286e287 C, IR cm1: 2713e2485 (NH). 1HNMR
(200MHz, DMSO‑d6) d: 3.88 (3H, s, CH3), 7.20 (1H, td, J¼ 2.4, 9.2 Hz,
AreH), 7.54 (1H, d, J¼ 5.0 Hz, AreH), 7.59e7.69 (2H, m, AreH), 7.78
(1H, dd, J ¼ 2.3, 9.6 Hz, AreH), 7.86 (1H, d, J ¼ 2.3 Hz, AreH), 8.47
(1H, s, AreH), 8.67 (1H, s, AreH), 10.04 (H, bs, NH). 13C NMR
(50 MHz, DMSO‑d6) d: 33.50 (q), 104.74 (d), 104.83 (s), 105.35 (d,
J ¼ 6.2 Hz), 110.73 (d), 111.45 (d, J ¼ 26.1 Hz), 112.65 (d, J ¼ 26.1 Hz),
120.84 (d), 124.15 (s), 124.37 (s), 125.39 (d), 127.36 (s), 133.08 (s),
133.93 (s), 135.03 (d), 140.25 (s, J ¼ 180.3 Hz), 157.62 (s). Anal. Calcd
for C17H12BrFN4S2 (MW: 435.33): C, 46.90; H, 2.78; N, 12.87. Found:
C, 47.01; H, 2.87; N, 12.95. LC-HRMS: 355.04926 m/z.5.1.4.7. 5-Bromo-3-[6-(thiophen-3-yl)imidazo[2,1-b] [1,3,4]thiadia-
zol-2-yl]-1H-indole (13c). Whitish solid, yield: 58%, m.p.
299e300 C, IR cm1: 3535e3633 (NH). 1HNMR (200 MHz,
DMSO‑d6) d: 7.39e7.44 (1H, m, AreH), 7.50e7.54 (2H, m, AreH),
7.59e7.63 (1H, m, AreH), 7.75 (1H, dd, J ¼ 1.1, 1.1 Hz, AreH), 8.32
(2H, d, J ¼ 1.7 Hz, AreH), 8.60 (1H, s, AreH), 12.29 (1H, s, NH). 13C
NMR (50 MHz, DMSO‑d6) d: 99.49 (s), 106.21 (s), 110.38 (d), 114.03
(s), 114.59 (d), 119.34 (d), 122.61 (d), 125.46 (d), 125.77 (d), 126.72
(d), 130.65 (d), 135.45 (s), 135.98 (s), 141.65 (s), 142.62 (s), 156.42 (s).
Anal. Calcd for C16H9BrN4S2 (MW: 401.30): C, 47.89; H, 2.26; N,
13.96. Found: C, 47.95; H, 2.31; N, 14.04. LC-HRMS: 402.95081 m/z.5.1.4.8. 5-Fluoro-3-[6-(thiophen-3-yl)imidazo[2,1-b] [1,3,4]thiadia-
zol-2-yl]-1H-indole (13g). Yellow solid, yield: 80%, m.p.
260e261 C, IR cm1: 3630 (NH). 1HNMR (200 MHz, DMSO‑d6) d:
7.16 (1H, td, J ¼ 2.5, 9.2 Hz, AreH), 7.52e7.63 (3H, m, 3xAr-H),
7.75e7.77 (1H, m, AreH), 7.84 (1H, dd, J ¼ 2.4, 9.8 Hz, AreH), 8.38
(1H, d, J ¼ 2.9 Hz, AreH), 8.55 (1H, s, AreH), 12.24 (1H, s, NH). 13C
NMR (50 MHz, DMSO‑d6) d: 99.40 (s), 104.61 (s), 105.78 (s), 111.36
(d), 113.77 (s), 120.20 (d), 123.70 (s), 123.96 (s), 126.46 (d), 128.11
(d), 131.63 (s), 133.24 (s), 135.45 (d), 138.25 (d), 140.74 (d), 145.68
(d). Anal. Calcd for C16H9FN4S2 (MW: 340.4): C, 56.45; H, 2.66; N,
16.46. Found: C, 56.51; H, 2.71; N, 16.56. LC-HRMS: 341.03256 m/z.
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diazol-2-yl]-1H-indole (13i). Yellow solid, yield: 58%, m.p.
255e256 C, IR cm1: 3628 (NH). 1HNMR (200 MHz, DMSO‑d6) d:
3.85 (3H, s, CH3), 6.95 (1H, dd, J ¼ 2.4, 8.8 Hz, AreH), 7.44 (1H, d,
J ¼ 8.8 Hz, AreH), 7.52e7.65 (3H, m, AreH), 7.75 (1H, dd, J ¼ 1.0,
2.8 Hz AreH), 8.24 (1H, d, J ¼ 3.0 Hz, AreH), 8.55 (1H, s, AreH),
12.00 (1H, s, NH). 13C NMR (50 MHz, DMSO‑d6) d: 55.32 (q), 102.18
(d),106.35 (s),110.30 (d),113.09 (d),113.30 (d),119.24 (d),124.34 (s),
125.52 (d), 126.66 (d), 129.59 (d), 131.61 (s), 136.07 (s), 141.49 (s),
142.55 (s), 155.09 (s), 157.08 (s). Anal. Calcd for C17H12N4OS2 (MW:
352.43): C, 57.93; H, 3.43; N, 15.90. Found: C, 57.88; H, 3.52; N,
15.99. LC-HRMS: 353.05377 m/z.
5.1.4.10. 5-Methoxy-1-methyl-3-[6-(thiophen-3-yl)imidazo[2,1-b]
[1,3,4]thiadiazol-2-yl]-1H-indole (13j). Yellow solid, yield: 60%, m.p.
213e214 C, 1HNMR (200MHz, DMSO‑d6) d: 3.86 (6H, s, OCH3, CH3),
6.99 (1H, dd, J ¼ 2.5, 7.7 Hz, AreH), 7.50e7.64 (4H, m, AreH), 7.75
(1H, d, J ¼ 3.2 Hz, AreH), 8.26 (1H, s, AreH), 8.55 (1H, s, AreH). 13C
NMR (50 MHz, DMSO‑d6) d: 33.24 (q, CH3), 55.38 (q, CH3), 99.49 (s),
102.32 (d), 105.06 (s), 110.35 (d), 111.90 (d), 112.96 (d), 119.24 (d),
124.61 (s), 125.52 (d), 126.67 (d), 132.30 (s), 133.03 (d), 136.00 (s),
141.46 (s), 142.43 (s), 155.37 (s), 156.63 (s). Anal. Calcd for
C18H14N4OS2 (MW: 366.46): C, 58.99; H, 3.85; N, 15.29. Found: C,
59.07; H, 3.91; N, 15.37. LC-HRMS: 367.06955 m/z.
5.1.5. General procedure for the synthesis 2-(1H-indol-3-yl)-6-
phenylimidazo[2,1-b] [1,3,4]thiadiazole-5-carbaldehydes 14k-r
Vilsmeier reagent was prepared at 0 C by adding dropwise
POCl3 (0.11 mL) into a stirred DMF anhydrous (0.08 mL). The
appropriate derivative 13 (0.5 mmol) in 2 mL of DMF anhydrous
was added and the solution was heated at 70 C under stirring for
5h. The reaction mixture was poured onto ice and the corre-
sponding aldehyde 14 was filtered off and purified by silica gel
column chromatography eluting by petroleum ether:ethyl acetate,
3:7.
Derivatives 14l, 14q were characterized only by 1HNMR spectra
due to their poor solubility.
5.1.5.1. 2-(1H-indol-3-yl)-6-phenylimidazo[2,1-b] [1,3,4]thiadiazole-
5-carbaldehyde (14k). White solid, yield: 70%, m.p. 285e286 C, IR
cm1: 2918 (NH), 1683 (CO). 1HNMR (200 MHz, DMSO‑d6) d: 7.30
(1H, m, AreH), 7.52 (2H, d, J ¼ 6.8 Hz, AreH), 8.01 (2H, d, J¼ 5.8 Hz,
AreH), 8.27e8.30 (3H, m, AreH), 8.41 (2H, d, J ¼ 3.0 Hz, AreH),
10.08 (1H, s, CHO),12.20 (1H, s, NH). 13C NMR (50MHz, DMSO‑d6) d:
106.20 (s), 112.64 (d), 120.65 (d), 121.70 (d), 123.36 (d), 123.47 (s),
123.80 (s), 128.67 (4xd), 129.41 (d), 130.10 (d), 132.38 (s), 136.68 (s),
148.53 (s), 153.45 (s), 159.38 (s), 177.31 (d). Anal. Calcd for
C19H12N4OS (MW: 344.39): C, 66.26; H, 3.51; N, 16.27. Found: C,
66.35; H, 3.59; N, 16.41. LC-HRMS: 345.08148 m/z.
5.1.5.2. 2-(1-Methyl-1H-indol-3-yl)-6-phenylimidazo[2,1-b] [1,3,4]
thiadiazole-5-carbaldehyde (14l). White solid, yield: 91%, m.p.
233e234 C, IR cm1: 1560 (CO). 1HNMR (200 MHz, DMSO‑d6) d:
3.90 (3H, s, CH3), 7.31e7.59 (6H, m, AreH), 7.87e8.41(4H, m, AreH),
10.07 (1H, s, CHO). Anal. Calcd for C20H14N4OS (MW: 358.4):
Composition: C, 67.02; H, 3.94; N, 15.63. Found: C, 67.28; H, 4.11; N,
15.75. LC-HRMS: 214.09023 m/z.
5.1.5.3. 6-(4-Fluorophenyl)-2-(1H-indol-3-yl)imidazo[2,1-b] [1,3,4]
thiadiazole-5-carbaldehyde (14m). White solid, yield: 81%, m.p.
255e256 C, IR cm1:3158 (NH), 1560 (CO). 1HNMR (200 MHz,
DMSO‑d6) d: 7.28e7.38 (4H, m, AreH), 7.52e7.55 (1H, m, AreH),
8.08e8.11 (2H, m, AreH), 8.26e8.29 (1H, m, AreH), 8.40 (1H, s,
AreH), 10.09 (1H, s, CHO), 12.19 (1H, s, NH). 13C NMR (50 MHz,
DMSO‑d6) d: 99.5 (s), 106.1 (s), 112.5 (d), 115.3 (d), 115.8 (d), 120.6(d), 121.7 (d), 123.3 (d), 123.8 (2xs), 128.9 (s), 130.2 (d), 130.7 (d),
130.9 (d), 136.7 (s), 148.2 (s), 151.8 (s), 159.4 (s), 177.3 (d). Anal. Calcd
for C19H11FN4OS (MW: 362.38): C, 62.97; H, 3.06; N,15.46. Found: C,
63.05; H, 3.11; N, 15.53. LC-HRMS: 363.07043 m/z.
5.1.5.4. 2-(1H-indol-3-yl)-6-(3-methoxyphenyl)imidazo[2,1-b] [1,3,4]
thiadiazole-5-carbaldehyde (14n). White solid, yield: 60%, m.p.
278e279 C, IR cm1: 3308 (NH), 1560 (CO). 1HNMR (200 MHz,
DMSO‑d6) d: 3.84 (3H, s, CH3), 7.06 (1H, d, J ¼ 6.7 Hz, AreH),
7.29e7.32 (2H, m, AreH), 7.41e7.46 (1H, m, AreH), 7.55 (1H, dd,
J ¼ 3.1, 5.8 Hz, AreH), 7.61 (2H, m, AreH), 8.30 (1H, m, AreH), 8.42
(1H, d, AreH), 10.10 (1H, s, CHO), 12.20 (1H, s, NH). 13C NMR
(50MHz, DMSO‑d6) d: 55.2 (q), 99.49 (s), 106.2 (s), 113.5 (2xd),120.7
(d), 121.0 (d), 121.7 (d), 123.3 (d), 123.6 (s), 123.8 (s), 129.7 (2xd),
130.1 (d), 133.7 (s), 136.7 (s), 153.0 (s), 159.3 (s), 159.4 (s), 177.3 (d).
Anal. Calcd for C20H14N4O2S (MW: 374.42): C, 64.16; H, 3.77; N,
14.96. Found: C, 64.25; H, 3.51; N, 15.13. LC-HRMS: 375.09232 m/z.
5.1.5.5. 6-(2,5-Dimethoxyphenyl)-2-(1H-indol-3-yl)imidazo[2,1-b]
[1,3,4]thiadiazole-5-carbaldehyde (14o). Yellow solid, yield: 82%,
m.p. 268e269 C, IR cm1: 1561 (CO). 1HNMR (200 MHz, DMSO‑d6)
d: 3.75 (3H, s, CH3), 3.77 (3H, s, CH3), 7.02e7.18 (3H, m, AreH), 7.32
(2H, dd, J¼ 2.9, 5.8 Hz, AreH), 7.55e7.58 (1H, m, AreH), 8.28 (2H, d,
J ¼ 5.5 Hz, AreH), 8.42 (1H, s, AreH), 9.76 (1H, s, CHO), 12.21 (1H, s,
NH). 13C NMR (50MHz, DMSO‑d6) d: 55.5 (q), 55.9 (q), 99.5 (s),106.2
(s), 112.5 (d), 113.1 (d), 116.1 (d), 116.3 (2xd), 120.62 (s), 121.7 (d),
122.1 (s), 123.3 (d), 123.8 (s), 130.0 (d), 136.7 (s), 148.7 (s), 150.4 (s),
153.1 (s), 159.2 (s), 177.6 (d). Anal. Calcd for C21H16N4O3S (MW:
404.44): C, 62.36; H, 3.99; N, 13.85. Found: C, 62.49; H, 4.05; N,
13.63. LC-HRMS: 405.10297 m/z.
5.1.5.6. 6-(2,5-Dimethoxyphenyl)-2-(1-methyl-1H-indol-3-yl)imi-
dazo[2,1-b] [1,3,4]thiadiazole-5-carbaldehyde (14p). White solid,
yield: 70%, m.p. 216e217 C, IR cm1: 1667 (CO). 1HNMR (200 MHz,
DMSO‑d6) d: 3.75 (3H, s, CH3), 3.77 (3H, s, CH3), 3.92 (3H, s, CH3),
7.06 (1H, dd, J ¼ 2.9, 5.8 Hz, AreH), 7.17 (2H, m, AreH), 7.36e7.39
(2H, t, J ¼ 4.0 Hz, AreH), 7.64 (1H, d, J ¼ 8.8 Hz, AreH), 8.27 (1H, d,
J ¼ 10.4 Hz, AreH), 8.43 (1H, s, AreH), 9.76 (1H, s, CHO). 13C NMR
(50 MHz, DMSO‑d6) d: 33.2 (q), 55.5 (q), 55.97 (q), 99.5 (s), 105.1 (s),
108.5 (d), 111.1 (d), 113.1 (d), 116.1 (s), 116.3 (d), 118.73 (d), 120.68
(d), 122.0 (d), 123.4 (d), 123.9 (s), 124.1 (s),136.2 (s),137.3 (s), 148.6
(s), 150.4 (s), 153.0 (s), 158.8 (s), 177.6 (d). Anal. Calcd for
C22H18N4O3S (MW: 418.47): C, 63.14; H, 4.34; N, 13.39. Found: C,
63.21; H, 4.43; N, 13.48. LC-HRMS: 419.11682 m/z.
5.1.5.7. 2-(1H-indol-3-yl)-6-(4-nitrophenyl)imidazo[2,1-b] [1,3,4]
thiadiazole-5-carbaldehyde (14q). Yellow solid, yield: 75%, m.p.
314e315 C, IR cm1: 3311 (NH), 1561 (CO). 1HNMR (200 MHz,
DMSO‑d6) d: 7.31 (2H, d, J ¼ 2.9 Hz, AreH), 7.52 (1H, s, AreH),
8.34e8.43 (5H, m, AreH), 10.21 (1H, s, CHO), 12.23 (1H, s, NH). Anal.
Calcd for C19H11N5O3S (MW: 389.39): C, 58.61; H, 2.85; N, 17.99.
Found: C, 58.82; H, 2.73; N, 18.09. LC-HRMS: 390.06683 m/z.
5.1.5.8. 2-(5-Bromo-1H-indol-3-yl)-6-(2,5-dimethoxyphenyl)imi-
dazo[2,1-b] [1,3,4]thiadiazole-5-carbaldehyde (14r). White solid,
yield: 90%, m.p. 250e251 C, IR cm1: 3268 (NH),1654 (CO). 1HNMR
(200 MHz, DMSO‑d6) d: 3.76 (6H, d, J ¼ 3.9 Hz, 2xCH3), 7.08e7.18
(3H, m, AreH), 7.42e7.56 (2H, m, AreH), 8.45 (2H, d, J ¼ 10.3 Hz,
AreH), 9.76 (1H, s, CHO), 12.38 (1H, bs, NH). 13C NMR (50 MHz,
DMSO‑d6) d: 55.3 (q), 55.9 (q), 99.5 (s), 105.9 (s), 108.2 (s), 114.3 (s),
116.1 (d), 116.3 (d), 122.0 (s), 122.9 (d), 123.9 (s), 125.5 (s), 126.0 (d),
131.2 (d), 135.5 (s), 141.6 (d), 150.3 (s), 150.7 (d), 153.3 (s), 158.7 (s),
178.6 (d). Anal. Calcd for C21H15BrN4O3S (MW: 483.33): C, 52.18; H,
3.13; N, 11.59. Found: C, 52.39; H, 3.21; N, 11.70. LC-HRMS:
485.01031 m/z.
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5.2.1. Drugs and chemicals
The synthesized imidazothiadiazole compounds 12e14 were
dissolved in DMSO. The medium, foetal bovine serum (FBS), peni-
cillin (50 IUmL1) and streptomycin (50 mg mL1) were from Gibco
(Gaithersburg, MD, USA). All other chemicals were from Sigma
(Zwijndrecht, the Netherlands).
5.2.2. Cell culture
Capan-1 and Panc-1 cell lines, were purchased at the ATCC
(Manassas, VA, USA), while SUIT-2 cells were a generous gift from
Dr. Adam Frampton (Imperial College, London, UK). Panc-1R cells, a
gemcitabine-resistant sub-clone obtained by continuous incuba-
tion of Panc-1 with 1 mM of this drug, were achieved as described
previously [41]. The primary PDAC-3 culture was isolated from a
patient at Pisa Hospital as described previously [61]. The cell lines
were tested for their authentication by STRePCR, performed by
BaseClear (Leiden, the Netherlands). The cells were cultured in
RPMI-1640 (Roswell Park Memorial Institute 1640) supplemented
with 10% heat-inactivated FBS, 1% penicillin/streptomycin, or in
DMEM (Dulbecco’s Modified Eagle’s Medium), supplemented with
10% heat-inactivated FBS, 1% HEPES. The cells were kept in a hu-
midified atmosphere of 5% CO2 and 95% air at 37 C and harvested
with trypsin-EDTA. Not all these preclinical models allowed to
perform the different experiments to check antitumor properties of
new compounds. In particular, PDAC-3 cells were selected to form
spheroids which are more representative of the aggregation of
tumor cells in vivo, as also reported in our previous studies. All the
PDAC cells, i.e., Panc-1R, SUIT-2 and PDAC-3, but also Panc-1 and
Capan-1 cells were selected for thewound-healing assay because in
all these cells the exposure for 24 h with our compounds did not
result in pro-apoptotic or necrotic effects, allowing a reliable
analysis of the results. Capan-1 and SUIT-2 cells were selected for
Western blot, zymography and PCR assays because preliminary
analyses of the housekeeping protein GAPDH at the Western blot
showed that using lysates of these cells the Western blot images
were not “saturated” and were kept in the linear range (as revealed
by exposing blots to increasing times and drawing a plot of in-
tensity and time exposure). SUIT-2 cells were selected for the
PamChip array because of the lowest background noise observed in
preliminary experiments.
5.2.3. Cell growth inhibition
The in vitro antiproliferative activity of the new imidazothia-
diazole compounds 12a,b,d,e,f,h, 13c,g,i,j and 14k-r was evaluated
on a panel of pancreatic cancer cells by Sulforhodamine-B (SRB)
assay, both for primary cell cultures (PDAC-3) and for the immor-
talized cell lines (SUIT-2, Capan-1, Panc-1 and Panc-1R), following a
previously described protocol [42]. The cytotoxicity of the new
compounds 12a and 12b was also evaluated in the normal fibro-
blast cells Hs27. The results of these experiments allowed us to
calculate the selectivity index (SI, IC50 non-tumor cell line/IC50 tu-
mor cell line).
Cells were seeded into a 96-well flat-bottom plates in triplicate
in a volume of 100 mL (3 103 cells/well for SUIT-2, Panc-1, Panc-1R
and PDAC-3 cell lines, 5  103 cells/well for Capan-1 cells, and
8  103 cells/well for Hs27 cells) and incubated for 24 h at 37 C to
create a confluent monolayer. Then, the cells were treated with
100 mL of the compounds dissolved in DMSO at different concen-
tration (125e16000 nM) for 72 h at 37 C, 5% CO2 and 100% hu-
midity. At the end of incubation period, the cells were fixed with
25 mL of 50% cold trichloroacetic acid (TCA) and kept for at least
60 min at 4 C. Then, the plates were emptied and washed gently
with deionized water, dried at room temperature (RT) overnightand stained with 50 mL of 0.4% SRB solution in 1% acetic acid for
15 min at RT. The excess of SRB stain was removed and the plates
were washed with a 1% acetic acid solution and let dry at RT
overnight. The SRB staining was dissolved in 150 mL of tris(hy-
droxymethyl)aminomethane solution pH¼ 8.8 (TRIS base), and the
absorbance was measured at wavelengths of 490 nm and 540 nm.
Cell growth inhibition was calculated as the percentage of drug
treated cells versus vehicle-treated cells (“untreated cells or con-
trol”) OD (corrected for OD before drug addiction, “day-0”). The 50%
inhibitory concentration of cell growth (IC50) was calculated by
non-linear least squares curve fitting (GraphPad PRISM, Intuitive
Software for Science, San Diego, CA). In the NCI protocol IC50 is
named GI50 (50% growth inhibitory concentration).
5.2.4. Wound-healing assay
The in vitro scratch wound-healing assay was performed as
previously described [62]. SUIT-2, Capan-1, Panc-1 and Panc-1R
cells were seeded in 96-well flat-bottom plates at the density of
5 104 cells/well in 100 mL. After 24 h of pre-incubation at 37 C, 5%
CO2 and 100% humidity, the cell monolayers were scratched using a
specific tool with multiple needles to create scratches of constant
width. After removal of the detached cells by washing with phos-
phate buffered saline (PBS) solution, in the control wells the me-
dium was replaced with only medium while the medium added
with the compounds of interest in the experimental wells. The
wound confluence was monitored by phase-contrast microscopy
(Universal Grab 6.3 software, Digital Cell Imaging Labs, Keerbergen,
Belgium) integrated to the Leica DMI300B (Leica Microsystems,
Eindhoven, Netherlands) migration station and the pictures were
captured immediately after scratch (T ¼ 0), and 4, 8, 20 and 24 h
from the treatment. The results were analyzed with the Scratch
Assay 6.2 software (Digital Cell Imaging Labs).
5.2.5. Spheroid assay
PDAC-3 spheroids were grown in CELLSTAR®96-well cell re-
pellent U-bottom plates (Greiner Bio-One, Cat No. 650970,
Kremsmünster, Austria). Cells were seeded at the density of
2  104 cells per well, and incubated at 37 C, 5% CO2 for 72 h in
order to let the spheroids form.
Before the treatment a picture of the plate was taken with an
automated phase-contrast microscope DMI300B (Leica Micro-
systems, Eindhoven, Netherlands), and the subsequent pictures
were taken every two days. After 72 h of incubation the culture
medium was replaced with medium added with compounds of
interest, whichwere diluted to the final concentration of 8.5 mM (5x
the IC50, obtained with previous growth-inhibition assay). Despite
the careful pipetting, tilting the plate and placing the pipette tip on
the side of the well, the structure of the spheroid was disturbed so
we decided to centrifuge the plate at 200xRCF, for 3 min at RT
(Rotixa 500RS, Hettich Zentrifugen Technology, Tuttlingen, Ger-
many). The treatment was repeated after four days, to ensure the
availability of nutrients, and so was the centrifuge.
Pictures were analyzed with ImageJ Software (U.S. National
Institute of Health, Bethesda, Maryland, USA) to determine the area
of the spheroids treated and compare it to the area of the untreated
spheroids, as described previously [63].
5.2.6. RNA isolation
RNA was extracted from SUIT-2, Capan-1 and Panc-1 cells ac-
cording to TRIzol-chloroform protocol as described previously [64].
Cells were seeded in a 6-well plate in a density of 2.5  105 cells/
well and kept at 37 C, with a constant level of CO2 (5%) and 100%
humidity for 24 h. Subsequently, the cells were treated for 24 h
with the compounds of interest at concentration 5x IC50 and stored
for an additional 24 h in the incubator. The cells were then
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isopropanol and washing with 70% ethanol, the total RNA appeared
as a white gel-like pellet at the bottom of the tube. RNA yields and
integrity were determined by measuring optical density at 260 nm
with a Thermo Scientific NanoDrop 1000™ Spectrophotometer,
controlled by ND1000 software. Instead, the test for detection of
contaminations by protein or by organic compounds, thiocyanates
and phenolate ionswas performed bymeasuring absorbance at 280
and 230 nm, respectively.
5.2.7. Reverse transcription (RT) and quantitative real-time PCR
(qRT-PCR)
For qRT-PCR, complementary DNA (cDNA) synthesis was per-
formed according to manufacturer’s protocol Thermo Scientific™
First Strand cDNA Synthesis Kit. For the reverse transcriptase re-
actions, 1.5 mg of mRNA was added to a 1 mL of random hexamer
primer and, finally, water nuclease free up to a final volume of 11 mL.
Therefore, 5X Reaction Buffer (4 mL), RiboLock RNase Inhibitor (20
U/mL) (1 mL), 10 nM dNTP Mix (2 mL) and M-MuLV Reverse Tran-
scriptase (20 U/mL) (2 mL) components were added (all provided by
Kit). The mixture was incubated for 5 min at 25 C followed by
60 min at 37 C. Subsequently, the reaction was terminated by
heating at 70 C for 5 min. The DNA samples obtained (20 mL) were
diluted 1:10 and used immediately for the RT-PCR assay. RT-PCR
reactions were performed using the commercial TaqMan® Uni-
versal PCR Master Mix kit. For the RT-PCR, 25 mL of total mix per
well is needed. Therefore, 12.5 mL of Universal Master Mix 2X
(AmpliTaq Gold DNA Polymerase, dNTPs with dUTP, passive refer-
ence, and optimized buffer components), 1 mL of Primers and Taq-
Man® probe, 6.5 mL of H2O and 5 mL of cDNA sample were loaded in
duplicate on a 96-well PCR plate and the amplification was carried
out in a GeneAmp 5700 Sequence Detection System. Samples were
amplified by following the thermal cycle conditions for 40 cycles:
an initial incubation at 50C for 2 min to prevent the ream-
plification of carry-over PCR products by AmpErase uracil-N-
glycosylase, followed by incubation at 95C for 10 min to sup-
press AmpErase UNG activity and denature the DNA, followed by
annealing and extension at 60 C for 1 min. Primers and probes
were obtained from Applied Biosystems Assay-on Demand Gene
expression products to amplify the following genes: SNAIL1
(Hs00195591_m1), SNAIL2 (Hs00950344_m1), CDH1 (Hs010
23894_m1), CDH12 (Hs00362037_m1). GAPDH (Hs02758991_g1)
has been used as housekeeping gene to normalize the amplifica-
tions. All reactions were performed in duplicate using the ABI
PRISM7500 sequence detection system instrument (AppliedBio-
systems). The cycle threshold (Ct) was determined and gene
expression levels relative to that of GAPDH were calculated by the
2DDCT method, as described previously.
5.2.8. Western blot and gelatine zymography
The protein expression of SNAIL1, SNAIL2, CDH1, CDH12, and
VIM in SUIT-2, PANC-1 and Capan-1 cells treated with compounds
12a and 12b was evaluated by Western Blot analysis as described
previously [65]. All the primary antibodies were from Cell Signal-
ling Technology (Beverly, MA). Additional Western blot analyses
were performed in order to evaluate the phosphorylation of FAK,
using the Phospho-FAK (Tyr397) Antibody #3283 (Cell Signalling
Technology).
The activity of MMP2 and MMP9 was evaluated by gelatine
zymography, as described previously [65]. PDAC cells (106) were
seeded in Petri dishes and incubated with serum-free medium for
24 h, with or without the selected compounds at 5x IC50. Medium
was harvested and centrifuged (1500 rpm for 5 min) in order to
remove cellular debris. The collected media were then mixed with
SDS-PAGE buffer 4X without reducing agent and underwentelectrophoresis in 10% polyacrylamide gel containing 1 mg/mL
gelatine. After 1 h, the gel was exposed to renaturating buffer
(50mM Tris-HCl pH 7, 6.5 mM CaCl2, 1 mMZnCl2, 2.5% Triton X-100)
for 15 min, washed with washing buffer (50 mM Tris-HCl pH 7,
6.5 mM CaCl2, 1 mM ZnCl2) and finally incubated with developing
buffer (50mM Tris-HCl pH 7, 6.5 mM CaCl2, 1 mMZnCl2, 1% Triton X-
100, 0.02% NaN3) for 16 h at 37 C. The staining was then performed
using 0.25% Coomassie Brilliant Blue R-250 solution containing 45%
methanol and 10% glacial acetic acid for 4 h, washed with a solution
of 10% glacial acetic acid and 45% methanol for 2 h. The areas of
protease activity were detected as clear bands and the activity of
MMPs was assessed by densitometric scanning and quantitative
analysis using ImageJ software (National Institutes of Health,
Bethesda, MD, US).
5.2.9. PamChip® kinase activity profiling
A PamChip array with 144 kinase peptides substrates (#86312
PamGene International B.V., ‘s-Hertogenbosch, The Netherlands)
was used to test the change in tyrosine kinase activity when using
the 12b compound. This experiment was performed with SUIT-
2 cells in biological duplicates (two untreated samples and two
treated samples with 12b compound), as described previously
[66,67].
5.2.10. Preparation of cell lysates
Cells were grown in 25 cm2 flasks until they reached 80% of
confluence, at 37 C and 5% of CO2, then SUIT-2 cells were treated
with 5 mM of 12b (5x IC50), and the medium of control cells was
replaced with fresh medium. Treatment lasted 24 h, and then cells
were lysed with 100 mL x 106 cells of M-PER lysis buffer containing:
M-PER Mammalian Extraction Buffer (Thermo Scientific, Rockford,
IL, USA), Halt protease Inhibitor cocktail, EDTA free (Complete Mini
EDTA-free Protease Inhibitor Cocktail, Roche #11836170001), Halt
Phosphatase Inhibitor Cocktail (Thermo Fisher #78420) both
diluted 1:100, for at least 15 min at 4 C. The lysates were collected
in 1.5 mL tubes, which were centrifuged (at 4 C, 16000g) for
15 min, and the supernatants were collected and stored at 80 C
until use. Protein concentration of the samples was determined
using Bio-Rad protein Assay, based on the method of Bradford (Bio-
Rad, Hercules, CA).
5.2.11. Tyrosine kinase activity profiling
Lysates for the PamChips were prepared in order to reach a
concentration of 10 mg protein/array, and they were added to the
MasterMix (PamGene reagent kit 32116) containing: PK buffer 10x,
BSA solution 100x, PTK additive 10x, 1 M DTT solution, Complete
Mini EDTA-free Protease Inhibitor Cocktail, Halt Phosphatase In-
hibitor Cocktail 400x (Thermo Fisher), PY-20-FITC (fluorescent
labelled antibody), 4 mM ATP solution. Samples were added to the
MasterMix immediately prior to loading on the chip. Before loading
the samples, the PamStation®12 instrument performed a blocking
step with 25 mL of 2% BSA on each array followed by three wash
steps with PK buffer, then 40 mL of each sample mix was loaded in
duplicate onto the arrays. During incubation at 30 C, the sample
mix was pumped up and down through the array once per minute
for 60 cycles. Repeated fluorescent imaging of each array was
performed with a 12-bit CCD camera, monitoring fluorescence in-
tensities in real time.
5.2.12. PamGene data analysis
The intensity of each spot at the end point was evaluated
through an open source software (ScanAnalyze) and subsequently
corrected for local background noise. Since the negative control
was a negative value, all the intensities were subjected to aminimal
shift to have the negative control equal to zero.
S. Cascioferro et al. / European Journal of Medicinal Chemistry 189 (2020) 11208816One duplicate of the treated samples was excluded from the
analysis due to bad quality data ending with two controls and one
treated samples. To maintain a balance and statistical power for the
differential analysis, one extra sample for the control group was
generated using the median of the two samples and adding a
constant k while 2 extra samples for the treated group were
generated adding a different constant k to the treated sample.
The differential analysis was performed by a Student t-test in R
(version 3.6.1) and the p.valuewas corrected by FDR. The significant
peptides were selected applying a cutoff on FDR <0.01. Visualiza-
tion of differentially phosphorylated protein was performed in
Cytoscape (version 3.5.0) and the barplot for PTK2 phosphorylation
was generated in R (version 3.6.1).
5.2.13. Enzyme-Linked Immunosorbent Assay (ELISA) for
phosphorylated FAK (pFAK) kinase
The pFAK level at tyrosine residue 397 was detected and
quantified using Enzyme-Linked Immunosorbent Assay (ELISA).
The assay was conducted using Invitrogen™ FAK [pY397] ELISA Kit
(Cat. # KHO0441) according to the manufacturer’s protocol. Su-
pernatants from Panc-1, Capan-1 and SUIT-2 cells were collected
after 24 h from the treatment with imidazothiadiazole compounds
12a and 12 b at concentration 5x IC50 value. The absorbance was
read at 450 nm. We performed a parallel ELISA test using the well-
known FAK inhibitor defactinib (5 mM). This drug reduced the FAK/
PTK2 phosphorylation of 65%, supporting the use of this method in
order to check the inhibition of pFAK.
5.2.14. Statistics
All SRB, PCR, Western blot, and zymography assays were carried
out in triplicate and repeated at least three times, whereas the
percentages of cell migrationwere calculated taking into account at
least six scratch areas. The data was evaluated using the GraphPad
Prism version 7 software (GraphPad Software, San Diego, CA, USA).
Data is expressed as mean values ± SEM and analyzed by the Stu-
dent t-test.
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CSI chlorosulfonyl isocyanateDMF Dimethylformamide
DMPM diffuse malignant peritoneal mesothelioma
DMSO Dimethyl sulfoxide
ELISA enzyme-linked immunosorbent assay
EMT epithelial mesenchymal transition
FAK focal adhesion kinase
FBS foetal bovine serum
FDR false discovery rate
GI50 growth inhibition of 50% of cells
IC50 inhibitory concentration 50%
MMP-2/9 matrix metalloproteinases-2/9
NCI National Cancer Institute
PDAC pancreatic ductal adenocarcinoma
PTK2 protein tyrosine kinase 2
RT room temperature
SD standard deviation
SEM standard error media
SI selectivity index
SNAIL-1/2 zinc finger protein-1/2
TGI total growth inhibition
VIM vimentinReferences
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